Sell Aarrestad Provan
Professor
https://orcid.org/0000-0001-5442-902X
https://orcid.org/0000-0001-5442-902X
Education
- Doctor (MD) at the Faculty of Medicine, University of Oslo (1996)
- Doctoral degree (PhD) at the University of Oslo (2011)
Position
- Senior physician in rheumatology, Diakonhjemmet hospital
- Senior researcher, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital
- Professor, section for public health, Innlandet University College
Field of interest
- Epidemiology, register data with a focus on comorbidities within inflammatory joint diseases and health economics
- Non-medicinal intervention research with the development of innovative digital tools for pre-treatment and monitoring
- Chronic pain conditions
- Biomarkers as outcome and surrogate marker for comorbidities
Other
- Co-leader work package 6 in REMEDY (Long-term follow-up)
Telephone
visiting address
Diakonhjemmet hospital
Diakonveien 12
0370 Oslo
Postal address
Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo
Projects
WP6 - Dechiphering long-term outcomes
NOECON
Health economics in the treatment of inflammatory arthritis diseases
Project Manager:
Sell Aarrestad Provan
Project Manager:
Tore K. Kvien
WP2 - PPhenotyping for personalized medicine
Nor-vaC
Immunological response to COVID-19 vaccine in patients on immunosuppressive treatment
Project Manager:
Guro Løvik Goll
WP5 - Innovative approaches to remote care
ReMonit
remote monitoring of patients with spondyloarthritis
Project Manager:
Nina Østerås
Project Manager:
Sell Aarrestad Provan
WP1 - Optimized medical interventions
SQUEEZE
Maximizing the effect of prescription drugs in rheumatoid arthritis
Project Manager:
Espen A. HaavardsholmPublications
Publications taken from the National Science Archive (NVA):
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
Sara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons, Brigitte Michelsen, Bente Glintborg, Bjorn Gudbjornsson
Seminars in Arthritis & Rheumatism
2024
Developing and externally validating multinomial prediction models for methotrexate treatment outcomes in patients with rheumatoid arthritis: results from an international collaboration
Celina K. Gehringer, Glen P. Martin, Kimme L. Hyrich, Suzanne MM Verstappen, Joseph Sexton, Eirik Kristianslund
Journal of Clinical Epidemiology
2024
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
Hilde Sofie Sager Ørbo, Kristin Reine Hammersbøen, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen
RMD Open
2024
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, Brigitte Michelsen, Tore Kristian Aaserud Kvien, Daniela Di Giuseppe, Johan K. Wallman
Journal of Rheumatology
2024
Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial
Inger Jorid Berg, Anne Therese Tveter, Gunnstein Bakland, Sarah Hakim, Eirik Kristianslund, Siri Lillegraven
JMIR Research Protocols
2023
Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease—results from the nationwide Norwegian Cardio-rheuma registry
Eirik Ikdahl, Silvia Christin Hellerud Rollefstad, Amirhossein Kazemi, Sella Aarrestad Provan, Trine-Lise Larsen, Anne Grete Semb
European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy
2023
How does current disease activity in rheumatoid arthritis affect the short-term risk of acute coronary syndrome? A clinical register based study from Sweden and Norway
Bénédicte Delcoigne, Sella Aarrestad Provan, Eirik Kristianslund, Johan Askling, Lotta Ljung
European journal of internal medicine
2023
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries
Bente Glintborg, Daniela Di Giuseppe, Johan Karlsson Wallman, Dan C Nordström, Bjorn Gudbjornsson, Merete Lund Hetland
Annals of the Rheumatic Diseases
2023
Exposure to specific tumor necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers
Benedicte Delcoigne, Tine Iskov Kopp, Elizabeth V. Arkema, Karin Hellgren, Sella Aarrestad Provan, Heikki Relas
RMD Open
2023
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses
Bente Glintborg, Ulf Lindström, Daniela Di Giuseppe, Sella Aarrestad Provan, Bjorn Gudbjornsson, Merete Lund Hetland
Arthritis care & research
2022
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: Results from four Nordic countries
Benedicte Delcoigne, Lotta Ljung, Sella Aarrestad Provan, Bente Glintborg, Merete Lund Hetland, Kathrine Lederballe Grøn
Annals of the Rheumatic Diseases
2022
Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumor necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
Ingrid Egeland Christensen, Siri Lillegraven, Mielnik Pawel, Gunnstein Bakland, Liz Paucar Loli, Joseph Sexton
Annals of the Rheumatic Diseases
2021
High-Intensity Exercise Improves Fatigue, Sleep, and Mood in Patients With Axial Spondyloarthritis: Secondary Analysis of a Randomized Controlled Trial
Silje Halvorsen Sveaas, Hanne Dagfinrud, Inger Jorid Berg, Sella Aarrestad Provan, Melissa Woll Johansen, Elisabeth Alexandersen Pedersen
Physical Therapy
2020
Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis
Hilde Berner Hammer, Brigitte Michelsen, Joe Sexton, Till Uhlig, Sella Aarrestad Provan
Clinical Rheumatology
2020
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naive patients with spondyloarthritis
Ulf Lindström, Bente Glintborg, Daniela Di Giuseppe, Dan C. Nordström, Sella Aarrestad Provan, Björn Gudbjörnsson
RMD Open
2019
Swollen, but not tender joints, are independently associated with ultrasound synovitis: Results from a longitudinal observational study of patients with established rheumatoid arthritis
Hilde Berner Hammer, Brigitte Michelsen, Joseph Sexton, Ida Kristin Haugen, Sella Aarrestad Provan, Espen A. Haavardsholm
Annals of the Rheumatic Diseases
2019
High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): A multicentre randomized trial of 100 patients
Silje Halvorsen Sveaas, Annelie Bilberg, Inger Jorid Berg, Sella Aarrestad Provan, Silvia Christin Hellerud Rollefstad, Anne Grete Semb
British Journal of Sports Medicine
2019
Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example
Katerina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, Daniela Di Giuseppe, Karin Hellgren, Bente Glintborg
RMD Open
2018
Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register
Sella Aarrestad Provan, Inge Christoffer Olsen, Cathrine Austad, Glenn Haugeberg, Tore Kristian Kvien, Till Uhlig
Seminars in Arthritis & Rheumatism
2017
CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: Results after 5-year follow-up
Inger Jorid Berg, Anne Grete Semb, Desirée van der Heijde, Tore Kristian Kvien, Inge Christoffer Olsen, Hanne Dagfinrud
Annals of the Rheumatic Diseases
2015
Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: A cross-sectional study
Inger Jorid Berg, Desirée van der Heijde, Hanne Dagfinrud, Ingebjørg Seljeflot, Inge Christoffer Olsen, Tore Kristian Kvien
Journal of Rheumatology
2015
The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: A 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and tociliziumab
Sella Aarrestad Provan, Inger Jorid Berg, Hilde Berner Hammer, Alexander Mathiessen, Tore Kristian Kvien, Anne Grete Semb
PLOS ONE
2015
Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: A cross-sectional comparative study
Silje Halvorsen Sveaas, Inger Jorid Berg, Sella Aarrestad Provan, Anne Grete Semb, Inge Christoffer Olsen, Thor Ueland
Scandinavian Journal of Rheumatology
2015
Effect of 1-Year Anti-TNF-alpha Therapy on Aortic Stiffness, Carotid Atherosclerosis, and Calprotectin in Inflammatory Arthropathies: A Controlled Study
Kristin Angel, Sella Aarrestad Provan, Magne Kristoffer Fagerhol, Petter Mowinckel, Tore Kristian Kvien, Dan Atar
American Journal of Hypertension
2012